Bob is right on. The only announcement which was even worth watching was the last one because they brought back tommy Marquez and Co. the open this year was an absolute joke. I watched the first one, w high anticipation, laughed my butt off in embarrassment and didn’t watch again until 5 when I heard Marquez was back. Also, good luck w the top athletes from countries with like 10 actual crossfitters. What’s the point of bringing in an athlete who will be ousted in the first 5 min of the games while Brent Filowski sits home? Good call
LOREN CORDAIN, Ph.D., is one of the top global researchers in the area of evolutionary medicine. Generally acknowledged as the world's leading expert on the Paleolithic diet, he is a professor in the Health and Exercise Science Department at Colorado State University. Dr. Cordain and his research have been featured on Dateline NBC and in the New York Times, the Wall Street Journal, and other media. He is the author of The Paleo Diet and The Paleo Diet Cookbook, among other books, and makes regular media and speaking appearances worldwide.
Workout 1 begins with the athlete’s rope on the floor and the athlete standing behind the rope. The barbell pre-loaded with the RX weight. At the start of the ascending clock, the athlete may pick up their rope and begin the workout. Athletes may take as many sets, breaking up the work as needed, to complete the required number of repetitions throughout the workout.
In court, Greg moved to block the sale. Lauren made a strong case. The $17.5 million, five-year payment plan he was offering was too risky, she said. In documents filed in court, she showed how much the company spent on what seemed to her like frivolous expenses, including an $11,000 a month lease on a house in San Diego and a $763,000 four-seater plane. The Anthos deal was cash, and she still says she honestly believes Anthos had CrossFit's best interests in mind. At one point, according to court filings, Anthos proposed that affiliates get 1 percent equity to cast a deciding vote where Anthos and Glassman disagreed.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”